Mina Habibizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mina Habibizadeh has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Parvin Mohammadi
Regenerative Medicine Research Center Health Technology Institute, Kermanshah University of Medical Sciences Kermanshah Iran
3 shared publicationsMahmoudreza Moradi
Regenerative Medicine Research Center Health Technology Institute, Kermanshah University of Medical Sciences Kermanshah Iran
2 shared publications- Ali Fattahi
Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
1 shared publication Amir Kiani
Regenerative Medicine Research Center Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran
1 shared publicationBabak Haghshenas
Regenerative Medicine Research Center Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran
1 shared publicationFarjam Goudarzi
Regenerative Medicine Research Center Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran
1 shared publication
Latest Publications
- 7 October 2026
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 114 (10)
Fabrication and Characterization of Bioengineered Sandwich Model Scaffold for Urethral Stricture Reconstruction
Urethral stricture remains a challenging clinical condition, particularly in patients with long or complex defects where suitable donor tissue is limited. Tissue engineering offers a promising alternative through the development of biomimetic scaffolds capable of restoring urethral structure and function. In this study, we fabricated a sandwich nanofibrous scaffold based on polyglycolic acid (PGA) and decellularized urethral extracellular matrix (uECM) using a sandwich design (uECM/PGA/uECM) and compared it with PGA and mix (PGA–uECM) scaffolds. Successful decellularization was confirmed by histological and molecular analyses, demonstrating effective removal of cellular components while preserving ECM architecture. Structural characterization revealed high porosity, enhanced hydrophilicity, favorable swelling behavior, and controlled degradation in ECM‐containing scaffolds. The uECM/PGA/uECM construct exhibited superior mechanical strength while maintaining suitable elasticity for urethral applications. Biological evaluation showed significantly improved endothelial cell adhesion, cell viability, and migration in ECM‐integrated scaffolds compared with PGA alone. In vivo implantation demonstrated excellent biocompatibility, absence of adverse inflammatory responses, and evident neovascularization. Overall, the sandwich uECM/PGA/uECM scaffold combines mechanical stability with bioactive functionality, highlighting its potential as a promising candidate for urethral tissue regeneration.
- 7 October 2026
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 114 (10)
Fabrication and Characterization of Bioengineered Sandwich Model Scaffold for Urethral Stricture Reconstruction
Urethral stricture remains a challenging clinical condition, particularly in patients with long or complex defects where suitable donor tissue is limited. Tissue engineering offers a promising alternative through the development of biomimetic scaffolds capable of restoring urethral structure and function. In this study, we fabricated a sandwich nanofibrous scaffold based on polyglycolic acid (PGA) and decellularized urethral extracellular matrix (uECM) using a sandwich design (uECM/PGA/uECM) and compared it with PGA and mix (PGA–uECM) scaffolds. Successful decellularization was confirmed by histological and molecular analyses, demonstrating effective removal of cellular components while preserving ECM architecture. Structural characterization revealed high porosity, enhanced hydrophilicity, favorable swelling behavior, and controlled degradation in ECM‐containing scaffolds. The uECM/PGA/uECM construct exhibited superior mechanical strength while maintaining suitable elasticity for urethral applications. Biological evaluation showed significantly improved endothelial cell adhesion, cell viability, and migration in ECM‐integrated scaffolds compared with PGA alone. In vivo implantation demonstrated excellent biocompatibility, absence of adverse inflammatory responses, and evident neovascularization. Overall, the sandwich uECM/PGA/uECM scaffold combines mechanical stability with bioactive functionality, highlighting its potential as a promising candidate for urethral tissue regeneration.
- Open Access
- 15 July 2026
- Published by Brieflands in Journal of Reports in Pharmaceutical Sciences
- Vol. 14 (1) , e168444
Fabrication and Characterization of an Engineered Graphene Oxide Quantum Dot-Polyethyleneimine-Hyaluronic Acid Nanocarrier: A Safe and Potentially Targetable Platform for Future Gene Therapy
Background: The global rise in cancer incidence underscores the urgent need for novel and more effective therapeutic strategies. Among emerging modalities, gene therapy offers a powerful and precise approach by directly modulating genetic pathways involved in tumor growth. However, the success of gene therapy depends critically on the development of safe, efficient, and target-specific carriers capable of condensing, protecting, and delivering nucleic acids to cancer cells with minimal toxicity. Objectives: This study aimed to develop and characterize a novel, biocompatible nanocarrier system based on graphene oxide quantum dots (GOQDs) functionalized with polyethylenimine (PEI) and hyaluronic acid (HA) for potential CD44-targeted gene delivery applications. Methods: The GOQD/PEI/HA nanocarrier was synthesized by covalent conjugation using EDC/NHS chemistry and characterized by Fourier transform infrared spectroscopy (FT-IR) and thermogravimetric analysis (TGA), which confirmed successful functionalization. DNA-binding and condensation were assessed by agarose gel retardation, and field-emission scanning electron microscopy (FE-SEM) was used to determine the size and surface morphology of the prepared complexes. Finally, hemocompatibility and cytocompatibility were evaluated using hemolysis test and MTT assay in HeLa cells. Results: TGA and FT-IR analyses confirmed the successful preparation of functionalized GOQD/PEI/HA NPs. The gel retardation assay demonstrated complete plasmid DNA (pDNA) condensation at a 1:2 pDNA-to-carrier ratio, confirming a strong electrostatic interaction between the DNA and the carrier. Hemolysis rates remained below 2% at all tested concentrations, demonstrating the high hemocompatibility of the carriers. Moreover, MTT assay results showed that HA conjugation significantly increased cell viability from approximately 76% for GOQD/PEI to above 90% for GOQD/PEI/HA, indicating a substantial reduction in GOQD/PEI-associated cytotoxicity. Conclusions: Collectively, these findings confirm that the covalently HA-modified GOQD/PEI nanocarrier effectively integrates strong gene-condensation capability with excellent biocompatibility and hemocompatibility. This system represents a promising and safe nonviral platform with the potential for targeted gene delivery to CD44-positive HeLa cancer cells. Future studies should assess its therapeutic efficacy in more physiologically relevant models, including 3D tumor spheroids, organoid cultures, and in vivo systems, to validate its potential for advanced cancer gene therapy applications.
- 15 July 2026
- Published by Brieflands in Journal of Reports in Pharmaceutical Sciences
- Vol. 14 (1) , e168444
Open AccessFabrication and Characterization of an Engineered Graphene Oxide Quantum Dot-Polyethyleneimine-Hyaluronic Acid Nanocarrier: A Safe and Potentially Targetable Platform for Future Gene Therapy
Background: The global rise in cancer incidence underscores the urgent need for novel and more effective therapeutic strategies. Among emerging modalities, gene therapy offers a powerful and precise approach by directly modulating genetic pathways involved in tumor growth. However, the success of gene therapy depends critically on the development of safe, efficient, and target-specific carriers capable of condensing, protecting, and delivering nucleic acids to cancer cells with minimal toxicity. Objectives: This study aimed to develop and characterize a novel, biocompatible nanocarrier system based on graphene oxide quantum dots (GOQDs) functionalized with polyethylenimine (PEI) and hyaluronic acid (HA) for potential CD44-targeted gene delivery applications. Methods: The GOQD/PEI/HA nanocarrier was synthesized by covalent conjugation using EDC/NHS chemistry and characterized by Fourier transform infrared spectroscopy (FT-IR) and thermogravimetric analysis (TGA), which confirmed successful functionalization. DNA-binding and condensation were assessed by agarose gel retardation, and field-emission scanning electron microscopy (FE-SEM) was used to determine the size and surface morphology of the prepared complexes. Finally, hemocompatibility and cytocompatibility were evaluated using hemolysis test and MTT assay in HeLa cells. Results: TGA and FT-IR analyses confirmed the successful preparation of functionalized GOQD/PEI/HA NPs. The gel retardation assay demonstrated complete plasmid DNA (pDNA) condensation at a 1:2 pDNA-to-carrier ratio, confirming a strong electrostatic interaction between the DNA and the carrier. Hemolysis rates remained below 2% at all tested concentrations, demonstrating the high hemocompatibility of the carriers. Moreover, MTT assay results showed that HA conjugation significantly increased cell viability from approximately 76% for GOQD/PEI to above 90% for GOQD/PEI/HA, indicating a substantial reduction in GOQD/PEI-associated cytotoxicity. Conclusions: Collectively, these findings confirm that the covalently HA-modified GOQD/PEI nanocarrier effectively integrates strong gene-condensation capability with excellent biocompatibility and hemocompatibility. This system represents a promising and safe nonviral platform with the potential for targeted gene delivery to CD44-positive HeLa cancer cells. Future studies should assess its therapeutic efficacy in more physiologically relevant models, including 3D tumor spheroids, organoid cultures, and in vivo systems, to validate its potential for advanced cancer gene therapy applications.
- 27 May 2026
- Published by Wiley in Macromolecular Bioscience
- Vol. 26 (5) , e00635
Angiogenesis: A Key to Advancing Urethral Engineering
Urethral stricture is a common urological condition in men that significantly affects quality of life. Autografts remain the gold standard for substitution urethroplasty; however, they present unavoidable limitations that tissue engineering seeks to overcome. One of the main challenges in long‐segment urethral strictures is achieving an effective graft capable of providing adequate oxygen and nutrient delivery, thereby preventing graft necrosis and failure. Therefore, both angiogenesis induction and mechanical integrity of the grafts are critical for successful urethroplasty. This review provides an integrated framework encompassing three complementary strategies for promoting angiogenesis in urethral tissue engineering: (i) angiogenesis guided substrates, (ii) growth factor delivery systems, and (iii) cell‐based therapies. Unlike previous reviews that focus on isolated aspects, our work provides a comprehensive and comparative discussion of these approaches within the specific context of urethroplasty. In addition, we highlight the translational challenges and pitfalls associated with each strategy, underscoring the need for standardized scaffold design, optimized cell culture protocols, and rigorous clinical validation. Despite ongoing progress, no optimal graft has yet been developed to ensure adequate vascularization for long segment urethral defects. Nevertheless, current findings suggest that angiogenesis induction holds promising potential for advancing urethral tissue engineering and improving clinical outcomes.
- 27 May 2026
- Published by Wiley in Macromolecular Bioscience
- Vol. 26 (5) , e00635
Angiogenesis: A Key to Advancing Urethral Engineering
Urethral stricture is a common urological condition in men that significantly affects quality of life. Autografts remain the gold standard for substitution urethroplasty; however, they present unavoidable limitations that tissue engineering seeks to overcome. One of the main challenges in long‐segment urethral strictures is achieving an effective graft capable of providing adequate oxygen and nutrient delivery, thereby preventing graft necrosis and failure. Therefore, both angiogenesis induction and mechanical integrity of the grafts are critical for successful urethroplasty. This review provides an integrated framework encompassing three complementary strategies for promoting angiogenesis in urethral tissue engineering: (i) angiogenesis guided substrates, (ii) growth factor delivery systems, and (iii) cell‐based therapies. Unlike previous reviews that focus on isolated aspects, our work provides a comprehensive and comparative discussion of these approaches within the specific context of urethroplasty. In addition, we highlight the translational challenges and pitfalls associated with each strategy, underscoring the need for standardized scaffold design, optimized cell culture protocols, and rigorous clinical validation. Despite ongoing progress, no optimal graft has yet been developed to ensure adequate vascularization for long segment urethral defects. Nevertheless, current findings suggest that angiogenesis induction holds promising potential for advancing urethral tissue engineering and improving clinical outcomes.
- 29 July 2024
- Published by SAGE Publications in Tissue Engineering Part B: Reviews
Engineered Tissues: A Bright Perspective in Urethral Obstruction Regeneration
The urethra reconstruction using tissue engineering is a promising approach in clinical and preclinical studies in recent years. Generally, regenerative medicine comprises cells, bioactive agents, and biomaterial scaffolds to reconstruct tissue. For the restoration of extended urethral injury are incorporated autologous grafts or flaps from the skin of the genital area and buccal mucosa are utilized. However, biomaterial grafts with cells or growth factors are investigated to enhance these grafts natural and synthetic biomaterials were investigated for pre-clinical studies in the form of decellularization tissues, nanofiber/ microfiber, film, and foam grafts that determined safety and efficiency. In this regard, skin grafts, bladder epithelium, buccal mucosa, small intestinal submucosa, tissue-engineered buccal mucosa, and polymeric nanofibers in clinical trials were examined, and promising and diverse outcomes were acquired. Even though, one of the challenges of the reconstruction of the urethra is resistance to urine pressure and its ability to be sutured, which could be solved by the proper adjustment of the physicochemical characteristics of the graft. Urethra engineering faces challenges due to necrosis caused by a lack of angiogenesis and fibrosis, which require further investigation in future studies.
- 29 July 2024
- Published by SAGE Publications in Tissue Engineering Part B: Reviews
Engineered Tissues: A Bright Perspective in Urethral Obstruction Regeneration
The urethra reconstruction using tissue engineering is a promising approach in clinical and preclinical studies in recent years. Generally, regenerative medicine comprises cells, bioactive agents, and biomaterial scaffolds to reconstruct tissue. For the restoration of extended urethral injury are incorporated autologous grafts or flaps from the skin of the genital area and buccal mucosa are utilized. However, biomaterial grafts with cells or growth factors are investigated to enhance these grafts natural and synthetic biomaterials were investigated for pre-clinical studies in the form of decellularization tissues, nanofiber/ microfiber, film, and foam grafts that determined safety and efficiency. In this regard, skin grafts, bladder epithelium, buccal mucosa, small intestinal submucosa, tissue-engineered buccal mucosa, and polymeric nanofibers in clinical trials were examined, and promising and diverse outcomes were acquired. Even though, one of the challenges of the reconstruction of the urethra is resistance to urine pressure and its ability to be sutured, which could be solved by the proper adjustment of the physicochemical characteristics of the graft. Urethra engineering faces challenges due to necrosis caused by a lack of angiogenesis and fibrosis, which require further investigation in future studies.
- 15 June 2021
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 109 (11) , 2237-2254
Surface modification of neurotrophin‐3 loaded PCL/chitosan nanofiber/net by alginate hydrogel microlayer for enhanced biocompatibility in neural tissue engineering
This study prepared a novel three‐dimensional nanocomposite scaffold by the surface modification of PCL/chitosan nanofiber/net with alginate hydrogel microlayer, hoping to have the privilege of both nanofibers and hydrogels simultaneously. Bead free randomly oriented nanofiber/net (NFN) structure composed of chitosan and polycaprolactone (PCL) was fabricated by electrospinning method. The low surface roughness, good hydrophilicity, and high porosity were obtained from the NFN structure. Then, the PCL/chitosan nanofiber/net was coated with a microlayer of alginate containing neurotrophin‐3 (NT‐3) and conjunctiva mesenchymal stem cells (CJMSCs) as a new stem cell source. According to the cross‐sectional FESEM, the scaffold shows a two‐layer structure with interconnected pores in the range of 20 μm diameter. The finding revealed that the surface modification of nanofiber/net by alginate hydrogel microlayer caused lower inflammatory response and higher proliferation of CJMSCs than the unmodified scaffold. The initial burst release of NT‐3 was 69% in 3 days which followed by a sustained release up to 21 days. The RT‐PCR analysis showed that the expression of Nestin, MAP‐2, and β‐tubulin III genes were increased 6, 5.4, and 8.8‐fold, respectively. The results revealed that the surface‐modified biomimetic scaffold possesses enhanced biocompatibility and could successfully differentiate CJMSCs to the neuron‐like cells.
- 15 June 2021
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 109 (11) , 2237-2254
Surface modification of neurotrophin‐3 loaded PCL/chitosan nanofiber/net by alginate hydrogel microlayer for enhanced biocompatibility in neural tissue engineering
This study prepared a novel three‐dimensional nanocomposite scaffold by the surface modification of PCL/chitosan nanofiber/net with alginate hydrogel microlayer, hoping to have the privilege of both nanofibers and hydrogels simultaneously. Bead free randomly oriented nanofiber/net (NFN) structure composed of chitosan and polycaprolactone (PCL) was fabricated by electrospinning method. The low surface roughness, good hydrophilicity, and high porosity were obtained from the NFN structure. Then, the PCL/chitosan nanofiber/net was coated with a microlayer of alginate containing neurotrophin‐3 (NT‐3) and conjunctiva mesenchymal stem cells (CJMSCs) as a new stem cell source. According to the cross‐sectional FESEM, the scaffold shows a two‐layer structure with interconnected pores in the range of 20 μm diameter. The finding revealed that the surface modification of nanofiber/net by alginate hydrogel microlayer caused lower inflammatory response and higher proliferation of CJMSCs than the unmodified scaffold. The initial burst release of NT‐3 was 69% in 3 days which followed by a sustained release up to 21 days. The RT‐PCR analysis showed that the expression of Nestin, MAP‐2, and β‐tubulin III genes were increased 6, 5.4, and 8.8‐fold, respectively. The results revealed that the surface‐modified biomimetic scaffold possesses enhanced biocompatibility and could successfully differentiate CJMSCs to the neuron‐like cells.